Charlotte Videbaek

Direktor/Vorstandsmitglied bei CESSATECH A/S

62 Jahre

Health Technology

Commercial Services

Consumer Services

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Adam Sinding Steensberg	M	50	CESSATECH A/S	4 Jahre
Martin Olin	M	55	CESSATECH A/S	4 Jahre
Flemming Steen Jensen	M	63	CESSATECH A/S	4 Jahre
Peter Birk	M	59	CESSATECH A/S	4 Jahre
Jes Trygved	M	51	H. LUNDBECK A/S CESSATECH A/S	8 Jahre
Rachel Curtis Gravesen	F	55	CESSATECH A/S	2 Jahre
Steen Henneberg	M	75	CESSATECH A/S	4 Jahre
Louise Bak	F	-	CESSATECH A/S	3 Jahre

Mehr sehen

Beziehungs-Chart

Beziehungen zu mehreren Unternehmen

Ehemalige Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Ulla Hald Buhl	F	60	CESSATECH A/S	1 Jahre
Jakob W. Gotfredsen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Uno Jakob Weber	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Christian Torp-Pedersen	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Lars Kober	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	3 Jahre
Benedikte Bandak	F	-	CESSATECH A/S	-
Jens Peter Balling	M	-	H. LUNDBECK A/S	-
Anders Götzsche	M	56	H. LUNDBECK A/S	15 Jahre
Iman Barilero	M	-	H. LUNDBECK A/S	-
Jørgen Okkels Nielsen	M	76	H. LUNDBECK A/S	5 Jahre
Marie-Laure Jeanne Antoinette Pochon	F	65	H. LUNDBECK A/S	5 Jahre
Kristian Sibilitz	M	-	H. LUNDBECK A/S	-
Christoffer Erik Lorenzen	M	48	H. LUNDBECK A/S	5 Jahre
Tugba Ceylan	F	-	H. LUNDBECK A/S	1 Jahre
Bettina Nygaard Nielsen	M	47	CESSATECH A/S	-
Inge Holm Lauritzen	F	57	H. LUNDBECK A/S	9 Jahre
Etienne Adriansen	M	60	CESSATECH A/S	-
Per Wold-Olsen	M	76	H. LUNDBECK A/S	4 Jahre
Klaus Bæk Simonsen	M	-	H. LUNDBECK A/S	-
Finn Eggert Sørensen	M	70	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Egil Bodd	M	69	H. LUNDBECK A/S	-
Mads Buhl Axelsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Frank Knudsen	M	66	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Carsten Schou	M	-	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Flemming Bent Lindeløv	M	75	H. LUNDBECK A/S	-
Hans Henrik Munch-Jensen	M	64	H. LUNDBECK A/S	8 Jahre
Peter Moldt	M	65	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Peter Bisgaard	M	50	Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	-
Helle Størum	F	57	H. LUNDBECK A/S	9 Jahre

Statistik

Land	Beziehungen	% des Gesamten
Dänemark	37	100,00%

Alter der Beziehungen

Aktive

Vergangene

Herr

Frau

Aufsichtsräte

Führungskräfte

Ursprung der Beziehungen

Börse
Insiders
Charlotte Videbaek
Persönliches Netzwerk